Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03544827 · ClinicalTrials.gov registry record · Phase 4
The Effects of Low Dose Atropine on Choroidal Thickness
A Phase 4 study, sponsored by State University of New York College of Optometry.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT03544827: Completed Phase 4 study, sponsored by State University of New York College of Optometry.
NCT03544827 is a Phase 4 study that has completed, run by State University of New York College of Optometry. The registered enrollment target is 36 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03544827, a Phase 4 study, has completed, sponsored by State University of New York College of Optometry.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
Atropine eye drops are considered to be an effective form of myopia control in human eyes. However, the mechanism by which it exerts it effects are not fully understood. Thickening of the choroid subsequent to atropine administration may play an important role in the mechanisms by which atropine induces myopia control. Literature also notes that choroidal thickness undergoes diurnal variations, which is a variable that will be controlled in this study in order to examine atropine's effects on different baseline choroidal thicknesses. The purpose of the proposed study is to characterize better the influence of atropine on choroid thickness. The study aims are to: 1. Determine the effect of low dose concentration of topical atropine (0.1% and 0.01%) on choroid thickness 2. Determine the effect of topical atropine on choroid thickness in relationship to baseline thickness throughout the day and after one week of daily instillation Hypothesis: Atropine's effect on choroidal thickness will be dependent on the subject's baseline thickness measurements, at a designated time of the day when the choroid is at its thinnest.
Primary Outcome
Measure choroidal thickness changes at baseline and compare to choroidal thickness after intervention of atropine 0.01% and atropine 0.1%
Interventions
- DRUG Atropine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-05-21 |
| Est. Completion | 2019-02-08 |
| Phase | Phase 4 |
What the finished NCT03544827 record still lists
NCT03544827 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which Atropine is the first listed.
NCT03544827 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03544827 about?
NCT03544827 is a clinical study titled "The Effects of Low Dose Atropine on Choroidal Thickness". Atropine eye drops are considered to be an effective form of myopia control in human eyes. However, the mechanism by which it exerts it effects are not fully understood. Thickening of the choroid subsequent to atropine administration may play an important role in the mechanisms by which atropine ind...
What is the current status of trial NCT03544827?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2018-05-21. Estimated completion is 2019-02-08.
What interventions are being tested in trial NCT03544827?
The interventions under investigation include: Atropine (DRUG).
Who is sponsoring clinical trial NCT03544827?
This trial is sponsored by State University of New York College of Optometry, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03544827's enrollment target sits among peer trials
36 1490th of 2000 higher than 495 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI